Use of a Transgenic Human PNPLA3 I148M Knock-in Mouse for Translational Safety Evaluations of siRNA Therapeutics
Nucleic Acid Therapeutics · 2025
DOI: 10.1177/21593337251375804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2025. Verfasst von Ben Brooks und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Safety & Risk Sciences, Amgen, Inc, Thousand Oaks, California, USA. Hauptthemen laut MEDLINE: RNA, Small Interfering, Lipase, Membrane Proteins, Fatty Liver. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
The PNPLA3 single nucleotide polymorphism, rs738409, is the strongest known genetic risk factor for metabolic dysfunction-associated steatotic liver disease; thus, targeting the minor allele with a GalNAc-conjugated siRNA is an attractive strategy to treat patients carrying the genetic variant. To enable translational safety assessment of a GalNAc-conjugated siRNA that specifically targets the rs738409 sequence of PNPLA3, a transgenic human PNPLA3I148M knock-in mouse (huPNPLA3I148M) was utilized. This model showed no significant genotype-related phenotypic differences to wild-type mice in a phenotype characterization study when maintained on standard rodent chow. Additionally, a repeat-dose toxicology study using a GalNAc-conjugated siRNA specific for rs738409 resulted in comparable findings between genotypes (i.e., liver enzyme and histopathology changes), indicating the findings were due to the siRNA therapeutic and not a result of target knockdown in huPNPLA3I148M mice. Overall, these data demonstrate the huPNPLA3I148M mouse is suitable for repeat-dose toxicology studies, suggesting this approach could be applied to other siRNA programs lacking a pharmacologically relevant nonclinical species to support translational safety assessments during drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Safety & Risk Sciences, Amgen, Inc, Thousand Oaks, California, USA.
- Translational Safety & Risk Sciences, Amgen, Inc, South San Francisco, California, USA.
- Pharmacokinetics & Drug Metabolism, Amgen, Inc., South San Francisco, California, USA.
- Lead Discovery & Characterization, Amgen, Inc., South San Francisco, California, USA.
- Genetic Medicine, Therapeutic Discovery, Amgen, Inc., Thousand Oaks, California, USA.
- Cardiometabolic Disorders, Amgen, South San Francisco, California, USA.
ORCID-Profile: Ingrid C Rulifson, Tod A Harper
Zitieren
APA
Brooks, B., Shkumatov, A., Kalanzi, J., Henderson Park, K., Lade, J. M., Wong, D., Dou, H., Long, J., Rulifson, I. C., Murray, J. K., Mihalcik, L., & Harper, T. A. (2025). Use of a Transgenic Human PNPLA3 I148M Knock-in Mouse for Translational Safety Evaluations of siRNA Therapeutics. Nucleic Acid Therapeutics. https://doi.org/10.1177/21593337251375804
Vancouver
Brooks B, Shkumatov A, Kalanzi J, Henderson Park K, Lade JM, Wong D, et al. Use of a Transgenic Human PNPLA3 I148M Knock-in Mouse for Translational Safety Evaluations of siRNA Therapeutics. Nucleic Acid Therapeutics. 2025. doi:10.1177/21593337251375804
BibTeX
@article{Brooks2025,
author = {Brooks, Ben and Shkumatov, Artem and Kalanzi, Jackson and Henderson Park, Kim and Lade, Julie M and Wong, Diana and Dou, Hui and Long, Jason and Rulifson, Ingrid C and Murray, Justin K and Mihalcik, Lauren and Harper, Tod A},
title = {Use of a Transgenic Human PNPLA3 I148M Knock-in Mouse for Translational Safety Evaluations of siRNA Therapeutics},
journal = {Nucleic Acid Therapeutics},
year = {2025},
doi = {10.1177/21593337251375804}
}
EUVIMED